Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

128.12 +0.36 (+0.28%)
Official Closing Price Updated: 7:00 PM EDT, Jul 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,918,615
Open 128.00
Bid (Size) 125.09 (1)
Ask (Size) 128.30 (1)
Prev. Close 127.76
Today's Range 127.20 - 128.34
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.28%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Merck's Acquisition of EyeBio Finalized
Merk announced the acquisition of EyeBio, introducing a novel candidate to the company's pipeline, Restoret. 
Via Benzinga

Performance

YTD
+13.14%
+13.14%
1 Month
+0.49%
+0.49%
3 Month
+1.53%
+1.53%
6 Month
+8.13%
+8.13%
1 Year
+21.36%
+21.36%

More News

Read More
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Via Benzinga
Merck Completes Acquisition of EyeBio
From Merck & Co., Inc.
Via Business Wire
3 Under-$10 Biotech Stocks That Could Make You Rich
Via InvestorPlace
Beyond The Numbers: 6 Analysts Discuss Merck & Co Stock
Via Benzinga
Merck & Co Unusual Options Activity
Via Benzinga
Insights Into Merck & Co's Performance Versus Peers In Pharmaceuticals Sector
Via Benzinga
7 Healthcare Stocks to Buy for Positive Inflation-Adjusted Returns
Via InvestorPlace
S&P 500 2024 Q2 Earnings Preview: Aggregate Earnings Reaching A New High Watermark?
Via Talk Markets
Topics Stocks
Exposures US Equities
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
Merk Animal Health Completes Acquisition of Elanco Animal Health Assets
Via Benzinga
Market Whales and Their Recent Bets on MRK Options
Via Benzinga
3 Undervalued Blue-Chip Stocks Ready for a Big Comeback
Via InvestorPlace
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
From Merck & Co., Inc.
Via Business Wire
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients
Via Benzinga
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
Beat the CPI: 7 Blue-Chip Stocks Growing Faster Than Inflation
Via InvestorPlace
mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
Via Benzinga
Exposures COVID-19
5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Merck Stock On Monday?
Via Benzinga
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
From Merck & Co., Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.